Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data
Oxford BioTherapeutics said Thursday that it has extended its second collaboration with Boehringer Ingelheim for another two years. The biotech said that the extension will add more programs to allow for developing “novel cancer immunotherapies” in indications with a higher unmet need.
The San Jose, CA-based biotech has been a partner with the private German pharma since 2013, when the companies first inked an oncology deal using Oxford’s discovery platform, called OGAP. The second deal was confirmed in 2020 to discover additional selective targets for “strategic cancer indications,” again with Boehringer using Oxford’s OGAP platform and combined with Boehringer’s T-cell engager, cancer vaccine and oncolytic virus platforms.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters